Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Encorafenib Plus Cetuximab in <i>BRAF</i>-V600E-Mutated Locally Advanced Colon Cancer.

JCO precision oncology·2025
Same author

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort.

Cancers·2022
Same author

Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.

World journal of surgical oncology·2022
Same author

A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

Journal of personalized medicine·2022
Same journal

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) <i>vs.</i> liver transplantation for borderline-resectable colorectal liver metastases: evidence not yet definitive.

Hepatobiliary surgery and nutrition·2026
Same journal

Immune-mediated tumor regression and subsequent escape driven by antigen loss and major histocompatibility complex (MHC) class I downregulation following GPC3 DNA vaccination in hepatocellular carcinoma.

Hepatobiliary surgery and nutrition·2026
Same journal

The evolution of liver graft preservation strategies in liver transplantation.

Hepatobiliary surgery and nutrition·2026
Same journal

Adjuvant therapy after R0 resection for primary hepatic sarcomatoid carcinoma.

Hepatobiliary surgery and nutrition·2026
Same journal

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Hepatobiliary surgery and nutrition·2026
Same journal

Revisiting treatment paradigms for colorectal liver metastases: liver transplant or associating liver partition and portal vein ligation for staged hepatectomy?

Hepatobiliary surgery and nutrition·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Biliary tract cancers: topaz-1 up-date, a practice changing study

Matthieu Sarabi1, Pascal Artru1

  • 1GELMAD - Institut de Cancerologie Mermoz, Lyon, France.

Hepatobiliary Surgery and Nutrition
|December 12, 2025
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Related Experiment Videos

Last Updated: Jan 8, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K